Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxart Inc (NQ: VXRT )

0.6035 +0.0042 (+0.70%)
Streaming Delayed Price Updated: 11:14 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxart Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Vaxart Traders Should Not Dismiss the Vaccine Maker’s Momentum
The recently range-bound price action of VXRT stock doesn't reflect the progress that Vaxart is making against Covid-19. 
Via InvestorPlace
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
Via FinancialNewsMedia
Exposures COVID-19
It’s Time to Start Thinking Seriously About Vaxart
While VXRT stock is risky due to underlying clinical challenges, the evolving nature of Covid-19 makes it worth consideration. 
Via InvestorPlace
Topics Government
Exposures COVID-19 Political
Unusual Options Activity Insight: Vaxart
Vaxart (NASDAQ:VXRT) shares experienced unusual options ac... 
Via Benzinga
Unusual Options Activity Insight: Vaxart
Shares of Vaxart (NASDAQ:VXRT) saw some unusual options a... 
Via Benzinga
Vaxart Looks To Be On The Verge Of Breaking Out Of A Pattern
Vaxart Inc. (NASDAQ: VXRT) shares are trading lower Monday, possibly after retail traders were able to push the stock higher. The stock looks to be almost breaking out of a... 
Via Benzinga
Vaxart Stock Is One Vaccine Also-Ran Worth Another Look
The jury's out whether its oral Covid-19 vaccine will be successful, but VXRT stock may still be worth it as a speculative play. 
Via InvestorPlace
Exposures COVID-19
Is Vaxart Stock Really Worth a Shot?
VXRT stock still has hope as Vaxart is developing modern rDNA vaccines in pill form (including a Covid-19 vaccine). 
Via InvestorPlace
Exposures COVID-19
Longshot Covid Play Vaxart Stock Is Too Risky at These Prices
Vaxart got approval Aug. 2 for a Phase II trial for its oral Covid-19 vaccine. VXRT stock has gained since, but it's still too pricey. 
Via InvestorPlace
Exposures COVID-19
Vaxart Is Another Risky Biotech Stock to Avoid Right Now
VRXT stock is highly overvalued. Investors are holding out for its Covid-19 vaccine, but it may not be approved in time to boost shares. 
Via InvestorPlace
Exposures COVID-19
The Delta Variant Is a Shot in the Arm for Vaxart’s Pill Vaccine
With many unvaccinated and the Delta variant a growing danger, VXRT stock has a good chance to increase in value in the coming future. 
Via InvestorPlace
Exposures COVID-19
Vaxart Stock Probably Isn’t Worth the Risk as It Pushes Higher
Vaxart’s oral recombinant vaccines are an interesting approach. Whether they do anything for VXRT stock remains to be seen. 
Via InvestorPlace
Why Shares of Vaxart Are Soaring Today
Some encouraging news for this troubled biotech. 
Via The Motley Fool
Exposures COVID-19
28 Stocks Moving in Friday's Pre-Market Session
Gainers Sphere 3D Corp. (NASDAQ: ANY) shares rose 35.4% to $4.66 in pre-market trading after the company reported an Agreement to acquire exclusive rights for assignment of... 
Via Benzinga
The Bull Thesis for VXRT Stock is Questionable at Best
Vaxart is far too risky for far too little 
Via InvestorPlace
California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers
Via FinancialNewsMedia
Exposures COVID-19
Why Vaxart's Stock Price Is Being Compressed In A Pennant Pattern And Looks Ready To Break Soon
Vaxart Inc. (NASDAQ: VXRT) shares pushed higher Monday after the company made an announcement stating the U.S. Food and Drug Administration cleared its Investigational New Drug... 
Via Benzinga
VXRT Stock: The Big FDA News Sending Vaxart Shooting Higher Today
VXRT stock is bulking up today. The company is getting approval from the FDA regarding its Covid vaccine, allowing for further research. 
Via InvestorPlace
Exposures COVID-19 Product Safety
Vaxart Stock Is Trading Higher As FDA Clears Mid-Stage Trial For S-Only Oral COVID-19 Vaccine Candidate
The FDA has signed off Vaxart Inc's (NASDAQ: VXRT) Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. "This is... 
Via Benzinga
Exposures COVID-19 Product Safety
Why Vaxart's Stock Is Trading Higher Today
Vaxart Inc (NASDAQ: VXRT) is trading higher Monday morning after the company announced the U.S. Food and Drug Administration cleared its Investigational New Drug... 
Via Benzinga
Understanding Vaxart's Unusual Options Activity
Shares of Vaxart (NASDAQ:VXRT) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $7.91. Sentiment: BEARISH Option... 
Via Benzinga
Vaxart Stock Shoots Higher After Its Oral Vaccine Boosts Immune Response In Previously Vaccinated Subject
Vaxart Inc's (NASDAQ: VXRT) has disclosed data from a 12-subject Phase 1b blinded study evaluating the ability of its oral norovirus vaccine to boost... 
Via Benzinga
Why Vaxart's Stock Is Surging Higher Today
Vaxart Inc (NASDAQ: VXRT) is trading higher Thursday morning after the company announced that it has shown, for the first time in clinical trials, that its oral tablet... 
Via Benzinga
Vaxart Stock Has Built-In Value Well Beyond Its Covid Pill
You can buy VXRT stock for the company's tablet-based Covid-19 vaccine, and hold it for Vaxart's other clinical breakthroughs. 
Via InvestorPlace
Exposures COVID-19
Vaxart Is Gaining Relevance, But Its Future Is Still Uncertain
Vaxart may have a second chance at prominence with its Covid-19 vaccine pill. But VXRT stock is still a largely speculative buy. 
Via InvestorPlace
Exposures COVID-19
Why Shares of Vaxart Jumped 31.2% in the First Half of 2021
The first half has been a cycle of hope and disappointment for shareholders. 
Via The Motley Fool
Why Coronavirus Stocks Are Zooming Higher Today
The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products. 
Via The Motley Fool
Topics Death
Exposures COVID-19 Death
3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street
Analysts' high-water price targets imply some serious gains for these companies. 
Via The Motley Fool
Topics Economy
Exposures COVID-19 Economy
Don’t Count on a Covid-19 Boost for Vaxart
VXRT stock remains a speculative bet as the company's chance to develop an oral Covid-19 vaccine grows slimmer every day. 
Via InvestorPlace
Exposures COVID-19
New Developments Have Made Vaxart Stock So Much More Attractive
Vaxart recently made a licensing deal, and two research firms issued upbeat assessments of the company, making me more upbeat on VXRT stock. 
Via InvestorPlace
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.